Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral T-cell lymphomas: Real-world insights into clinical features and prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRodrigo Figueroa-MéndezACAmairani Carpintero-Díaz

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows advanced disease worsens prognosis in patients with T-cell lymphomas, indicating urgent need for better access to treatments.

Key Points

  • To evaluate clinical features and survival outcomes of peripheral T-cell lymphomas in a Mexican cohort.
  • Conducted a retrospective analysis of 128 patients with PTCL at a national referral center in Mexico from 2011 to 2024.
  • Analyzed overall survival and progression-free survival using Kaplan-Meier curves and log-rank tests.
  • Documented clinical features and treatment responses, including first-line treatment and laboratory parameters.
  • Median overall survival was 15 months, with 54.6% overall response rate.
  • Advanced disease stage and high-risk scores were associated with increased mortality.
  • Brentuximab-based therapy showed the best overall survival among treatment strategies.

Cite This Study

Figueroa-Méndez et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2d9https://doi.org/10.1182/blood-2025-5421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes2026
  2. 2Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025
  3. 3How I treat peripheral T-cell lymphomas2024 · 1 citations
  4. 4Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea2025 · 1 citations
  5. 5Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified2026